http://www.molecularpartners.com  

8952 Schlieren, Wagistrasse 14

 +41 44 755 77 00

Molecular Partners AG is a clinical-stage biopharmaceutical company, located in Schlieren, Switzerland, that is developing a new class of therapies known as DARPin® therapies.

https://lightium.co/  

8952 Schlieren, Wagistrasse 13

Production-grade photonic foundry for thin-film lithium niobate

http://www.bio-technopark.ch/  

8952 Schlieren, Wagistrasse 23

 +41 76 336 99 44
 mario.jenni@bio-technopark.ch

The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.

https://dinaqor.com/  

8952 Schlieren, Wagistrasse 25

DiNAQOR’s mission is to develop gene therapy solutions that transform the lives of patients with heart disease. Our novel and innovative gene therapy platform is focused on advancing treatments for patients affected by genetic cardiomyopathies, a disease of the heart muscle that can lead to heart failure.

http://www.biognosys.ch/  

8952 Schlieren, Wagistrasse 21

 +41 44 738 20 40
 info@biognosys.ch

BiognoSYS provides proteomics solutions to scientists and clinicians.

http://www.neurimmune.com  

8952 Schlieren, Wagistrasse 18

 +41 44 755 46 46
 info@neurimmune.com

Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases.

http://cutiss.swiss  

8952 Schlieren, Grabenstrasse 11

 +41 44 244 36 60
 info@cutiss.swiss

After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.